SOURCE: IsoRay, Inc.

IsoRay, Inc.

June 23, 2015 08:30 ET

IsoRay Intends to Vigorously Defend Litigation

Retains Wilson Sonsini as Counsel

RICHLAND, WA--(Marketwired - Jun 23, 2015) - IsoRay, Inc. (NYSE MKT: ISR) has retained Wilson Sonsini Goodrich & Rosati to defend the Company and certain officers named in several lawsuits filed against it related to a press release on May 20, 2015.

The lawsuits relate to a May 20 Company press release, regarding a May 19 online publication of the peer-reviewed article in the journal Brachytherapy titled "Analysis of Stereotactic Radiation vs. Wedge Resection vs. Wedge Resection Plus Cesium-131 Brachytherapy in Early-Stage Lung Cancer" by Dr. Bhupesh Parashar, et al.

We believe the lawsuits are without merit and we intend to contest them vigorously.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: whether the pending litigation has merit, IsoRay's intention to contest the pending litigation vigorously, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as the actual claims made in the litigation, the complexities and expense of litigation, the uncertain nature of litigation and judicial processes, future developments with respect to the filed claims, the potential perceptions of the Company's current and future customers regarding the litigation, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information